Elevance Health (NYSE: ELV) recently reported its Q3 results, with revenues exceeding but earnings missing the consensus estimates. The company reported revenue of $44.7 billion and adjusted earnings of $8.37 per share, compared to the street estimates of $43.5 billion and $9.66, respectively.
Elevance Health's Q3 2024 results were disappointing with a significant increase in the benefit expense ratio and lowered earnings expectations for the full year. I take a close look at ELV's exposure to government plans and their profitability. I explain why I view Elevance stock as favorably valued even under very conservative near and long-term growth assumptions.
Elevance Health Inc. ELV reported weaker-than-expected earnings for its third quarter on Thursday.
Major U.S. equities indexes were mixed as earnings results from Taiwan Semiconductor Manufacturing (TSM) helped revitalize optimism around artificial intelligence (AI) and September retail sales data came in ahead of forecasts.
Elevance Health's Q3 earnings report led to a 14% stock price drop due to increased benefit expense ratio and declining EPS. The health insurance industry faces challenges, particularly in Medicare Advantage and Medicaid, affecting profitability and causing industry-wide share price declines. Elevance's management expects revenue growth in 2025 but acknowledges ongoing profitability issues, suggesting a cautious outlook for the near term.
ELV's third-quarter earnings are hurt by declining membership in Medicaid and Medicare, partially offset by improved product revenues.
Elevance Health Inc. ELV reported on Thursday third-quarter revenues of $44.7 billion, up 5.3% year-over-year, beating the consensus of $43.33 billion.
CNBC's Bertha Coombs reports on Elevance Health's quarterly earnings results.
Elevance Health (ELV) shares cratered Thursday after the insurer posted a lower-than-expected profit and slashed its outlook on falling Medicaid enrollments.
Although the revenue and EPS for Elevance Health (ELV) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
On Thursday, Elevance Health Inc. ELV reported third-quarter revenues of $44.7 billion, up 5.3% year-over-year, beating the consensus of $43.33 billion.
Elevance Health (ELV) came out with quarterly earnings of $8.37 per share, missing the Zacks Consensus Estimate of $9.70 per share. This compares to earnings of $8.99 per share a year ago.